ReviewNature reviews. Rheumatology2015
A vascular mechanistic approach to understanding Raynaud phenomenon.
Review in Nature reviews. Rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Raynaud's Phenomenon of the Nipple: Epidemiological, Clinical, Pathophysiological, and Therapeutic Characterization.International journal of environmental research and public health · 2024Pooled it
- Peripheral vasoconstriction induced by β-adrenoceptor blockers: a systematic review and a network meta-analysis.British journal of clinical pharmacology · 2016Pooled it
- Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.British journal of clinical pharmacology · 2016Pooled it
- Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.Arthritis & rheumatology (Hoboken, N.J.) · 2017Trial
- The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2017Trial
- Botulinum Toxin Vascular Effectiveness: Low or High Doses?Aesthetic plastic surgery · 2026Review
- Drug-Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue-Related Raynaud Phenomenon in the United States.Arthritis care & research · 2026Review
- Risk of Venous Thromboembolism in Patients with Presumed Primary Raynaud's Syndrome: A Propensity-Matched Study Using the TriNetX Database.International journal of medical sciences · 2026Article
- Skin transient receptor potential channels expression and microvascular reactivity to cooling in primary and secondary Raynaud's phenomenon.Physiological reports · 2025Article
- NMR based clinical metabolomics revealed altered lipid and sugar metabolism in systemic sclerosis with implications for diagnosis and therapeutic strategies.Scientific reports · 2025Article
- Advancements in Managing Intractable Raynaud Phenomenon: The Role of Integrated Neurectomy and Sympathectomy.Seminars in plastic surgery · 2025Review
- Cold responses and hormonal echoes: a comprehensive view of Raynaud's vascular dysfunction.Inflammopharmacology · 2025Review
- α2 adrenoceptors, cold-induced vasoconstriction, and Raynaud's phenomenon.Cell genomics · 2025Article
- The Effects of Botulinum Toxin on Vascular Diameter: A Preliminary Report.Journal of cosmetic dermatology · 2025Article
- Article
- Revisiting the Venoarteriolar Reflex-Further Insights from Upper Limb Dependency in Healthy Subjects.Biology · 2024Article
- A case of misdiagnosed arterial thoracic outlet syndrome as primary Raynaud's phenomenon.Journal of vascular surgery cases and innovative techniques · 2024Article
- Blood biomarkers for occupational hand-arm vibration exposure.Toxicology and industrial health · 2024Article
- Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment.Vascular specialist international · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During exposure to cold, our bodies attempt to maintain normal core temperature by restricting heat loss through cutaneous vasoconstriction, and by increasing heat production through shivering and nonshivering thermogenesis. In selected areas of human skin (including on the fingers and toes), the vascular system has specialized structural and functional features that enable it to contribute to thermoregulation. These features include arteriovenous anastomoses, which directly connect the arterial and venous systems and bypass the nutritional capillaries supplying blood to the skin tissue. Of note, Raynaud phenomenon predominantly affects the arterial territories supplying these specialized areas of skin. Indeed, Raynaud phenomenon can be considered a disorder of vascular thermoregulatory control. This Review presents an understanding of Raynaud phenomenon in the context of vascular and thermoregulatory control mechanisms, including the role of unique thermosensitive vascular structural and functional specialization, and describes the potential role of thermogenesis in this disorder. This new approach provides remarkable insight into the disease process and builds a framework to critically appraise the existing knowledge base. This paradigm also explains the deficiencies in some current therapeutic approaches, and highlights new areas of potential relevance to the pathogenesis and treatment of Raynaud phenomenon that should be expanded and explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.